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Abstract  
Objectives 
To identify the clinical characteristics, reasons for use and response to treatment with 
anakinra in a series of patients with Kawasaki Disease (KD). 
Study design 
A retrospective chart review of patients treated with anakinra for KD diagnosed according to 
the AHA criteria. We compared clinical, biological and echocardiographic characteristics of 
KD before and after anakinra use. We analysed reasons for use of anakinra, and compared 
treatment regimens used in 7 European KD referral centres.  
Results 
Eight boys and 3 girls with treatment-refractory KD, aged 4 months to 9 years old, received 
at least 2 different KD treatments prior to anakinra, which was given on mean at 25 days 
after disease onset (8 to 87 days). The main reasons for use of anakinra were clinical and 
biological inflammation, progression of coronary dilatations, and severe myocarditis with 
cardiac failure. Doses of anakinra ranged from 2 to 8 mg/kg and duration varied from 6 to 81 
days. Efficacy of anakinra was judged in terms of fever resolution (100%), decrease of CRP 
(100%), and in terms of its effect on coronary artery dilatation Z scores, which decreased in 
10/11 patients and increased in one who died suddenly of pericardial hemorrhage. 
Conclusion 
Anakinra used late in the disease course led to a rapid and sustained improvement in clinical 
and biological inflammation. Our retrospective analysis did show neither a striking nor a 
rapid decrease of coronary dilatations and we cannot determine if anakinra itself had an 
effect on coronary artery dimensions.  
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Introduction 
Kawasaki disease (KD) is the most frequent vasculitis of children aged less than 5 years, and 
the main cause of acquired heart disease in developed countries. KD has also been seldom 
reported in young adults at a mean age of 30 years [1].  Epidemiologic data strongly suggest 
an infectious aetiology, although the causative agent has yet to be identified. Genetic factors 
also increase susceptibility to KD, as indicated by its strikingly high incidence in children of 
Asian ethnicity, both in and outside the Far East, and by an increased incidence in first-
degree family members [2, 3]. KD is a self-limited illness that results in coronary artery 
aneurysms in up to 25% of untreated children. Giant aneurysms, myocardial infarction and 
myocarditis are present in a minority of KD cases, and rarely lead to early death [4].  
Administration of high-dose intravenous immunoglobulin (IVIG) in combination with aspirin 
results in dramatic clinical improvement and reduced incidence of coronary artery 
aneurysms in the majority of patients with KD [5,6]. A subset (20%) of patients has 
persistence or recrudescence of fever following IVIG treatment, and are at increased risk for 
coronary vasculitis. The American heart association (AHA) has recommended administering a 
second dose of IVIG (2 g/kg) to patients who fail to become afebrile within 48 hours after 
completion of the first infusion, even though the benefits of this approach may be limited, 
especially in terms of efficacy on coronary abnormalities [7]. Identifying patients at risk for 
IVIG resistance is difficult outside the Asian population, and there remains a critical unmet 
need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Some 
clinical features of KD are similar to those observed in systemic autoinflammatory diseases 
(SAID), including systemic-onset juvenile idiopathic arthritis (SoJIA): abrupt and seemingly 
unprovoked onset of fever at a young age, skin rash, eye and mouth inflammation, cervical 
adenitis, and pericarditis. Marked elevation of acute phase reactants: e.g. CRP and 
neutrophils, elevated platelets, hypoalbuminemia without evidence of autoantibodies are 
also very concordant with soJIA. Intriguingly, transient coronary abnormalities have also 
been noticed in patients with soJIA [8].  Recent evidence from studies in animals and 
humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. For 
example, IL-1 polymorphisms could be associated either to response or resistance to IVIG 
treatment. Interestingly elevated transcripts have been shown in IVIG-resistant KD patients, 
those carrying the highest risk for coronary aneurysms [9, 10]. Of particular note, only 
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blockade of IL-1, but not of tumour necrosis factor (TNF) α, reduced the myocarditis in the 
LCWE (Lactobacillus casei cell wall extract)-injected mice and TNFα blockade as adjunctive 
therapy to IVIG gave success regarding fever and inflammatory parameters but with no 
differences in coronary artery evolution in a controlled trial in humans [11-14].  Anakinra has 
been reported to successfully treat KD in 3 patients not responding to standard treatment 
with IVIG [15-18].   
Due to its availability and its safety of use, anakinra is increasingly used off label to treat 
patients with other IL-1 related diseases [19, 20]. Here, we present further experience of 
anakinra use in order to identify the clinical characteristics, reasons for use and response to 
treatment with anakinra in a retrospective series of patients with KD. 
 
Patients and methods 
We collected retrospective data from KD patients treated with anakinra using a dedicated 
questionnaire. Patients were recruited in France through the SOFREMIP (SOciété 
Francophone de Rhumatologie Et de Médecine Interne Pédiatriques) network, and other 
European countries (Italy, Spain, United Kingdom) through an established international 
network on KD. Inclusion criteria were a diagnosis of KD according to the American Heart 
association (AHA) criteria for complete or incomplete KD, treatment with anakinra for KD, 
and sufficient available data for analyses. Recorded data included demographics, clinical, 
biological and echocardiographic characteristics of KD, and timing of treatments, history 
before and after anakinra. Data collected regarding anakinra treatment were: reasons for 
use, doses applied, and duration of treatment, concomitant treatments and any adverse 
event. Cardiologic findings were recorded before and after anakinra treatment, and at the 
last follow-up. Efficacy of anakinra was assessed by clinical (fever and symptoms of KD), 
biological (blood cell count, C-reactive protein: CRP), and cardiologic findings.  As we 
performed a retrospective chart review, there was institutional approval for collection of the 
data as part of an audit, without individual patient consent 
 
Results 
 
Clinical, biological and cardiologic characteristics 
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Eleven patients, 8 boys and 3 girls, were included. Age at symptom onset ranged from 4 
months to 9 years [median 22 months], and included 4 patients under 6 months. Nine 
patients fulfilled AHA criteria for complete KD and two for incomplete KD. The median delay 
to diagnosis was 8 days [mean 13 days; 3 to 50 days]. The mean disease follow-up from 
diagnosis was 8 months [1 to 31 months]. In addition to major AHA criteria, 90% of patients 
(9/10) were irritable, 70% had hepatomegaly (7/10), 3/11had digestive manifestations (pain, 
diarrhea), 22% hydrocholecystis (2/9), 3/11 had neck pain, and two were hypotonic (Table 
1). Two patients presented with acute cardiac failure (Kawasaki shock syndrome) and were 
admitted to intensive care units. The initial blood cell count was performed at a mean timing 
of 9 days (0 to 37 days) from the first symptom of KD (19 days before diagnosis to 4 days 
after diagnosis). Laboratory values at several time-points are presented in table 2. The first 
echocardiography was performed at a mean of 10.6 days (3 to 37 days) from the first 
symptom. Seven patients had coronary abnormalities at evaluation between day 3 to day 12 
of disease, and three others presented them subsequently. One patient had no cardiac 
complications. Z scores before anakinra were available in 10/11 patients and ranged from 
+2.5 to 12.4 (Table 3). Two patients had myocarditis, and one valvar dysfunction. 
Treatments 
The number of treatment modalities used was 3 in 3 patients, 4 in 2 patients, 5 in 3 patients, 
and ≥6 in 3 patients (Table 3). The first line was IVIG at the dosage of 2g/kg in all patients, 
which was administered at a delay of 3 to 50 days (mean: 13 days, median: 8 days) after the 
first symptom of KD. The second line was a second infusion of IVIG in 5 patients, infliximab in 
3 patients, and intravenous methylprednisolone in 3 patients given at 0.8 to 30 
mg/kg/infusion. The third line was intravenous methylprednisolone in 6 patients (0.8 to 30 
mg/kg/infusion), oral corticosteroids in 1 patient (1mg/kg/day), and IVIG in one patient. 
Anakinra was the third line in 3 patients. Others treatments were cyclosporine and 
methotrexate (n= 1 and 1). All patients were treated with aspirin (50 mg/kg/d); four received 
anticoagulants.  
All patients were treated with anakinra with a dosage ranging from 2mg/kg/d to 8 mg/Kg/d 
(Table 3). Anakinra was initiated on average at 25 days after disease onset (median 15 days, 
ranging from 8 to 87 days). It was associated with oral prednisone at 2mg/kg in 5 patients, 
cyclosporin at 3mg/kg in one and infliximab 5 mg/kg in another one. The main reasons for 
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use of anakinra were persistent fever (8/11); progressive coronary dilatation (7/11), 
persistent clinical symptoms (2/11), persistent blood inflammation (6/11), and Kawasaki-
related shock syndrome (severe myocarditis) in one case. On anakinra treatment, fever 
disappeared within hours (<24 h) in 3 patients, and within 2 and 6 days in two patients 
respectively. Six others patients were not febrile at onset of anakinra. In addition, CRP levels 
fell two to three fold within 48 hours in 7/9 evaluable patients. At the last echography, 
coronary abnormalities improved or normalized in 10/11 patients. One patient never had 
coronary abnormalities. Total clinical and cardiac recovery was obtained in 6/11 patients; 
most of them received anakinra at a maximum of 15 days after disease onset. Patient 11 had 
aneurysms and thrombosis of legs arteries and bowel ischemia. One patient had sudden 
death probably due to massive pericardial effusion secondary to giant aneurysm rupture 
under anticoagulants (no autopsy performed). The duration of treatment was highly variable 
from 6 to 81 days, and is still ongoing in two patients.  
Discussion 
We have presented the largest published case-series so far of patients with KD treated with 
anakinra. Common characteristics of these patients were IVIG resistance, cardiac 
complications (with cardiogenic shock in 2 cases), and at least two lines of other treatment 
before anakinra. It is well known that IVIG resistance is associated with coronary vasculitis 
and genetic studies have identified the inositol 1,4,5-trisphosphate 3-kinase C, (ITPKC) as a 
susceptibility factor for both KD and coronary aneurysm across diverse populations [3]. 
Polymorphisms in the ITPKC gene induce increased Ca++ flux into the mononuclear cell, 
NLRP3 inflammasome activation and increased secretion of IL-1β and IL-1α [21, 22]. In 
addition, it is known that IVIG decrease the level of proinflammatory cytokines (IL-1, IL-6 
and TNF) in responsive patients and that IVIG-resistant KD patients, have decreased 
expression of IL-1 receptor antagonist (IL1-Ra) [21-23]. Anakinra is an analog of the IL-1-Ra, 
which blocks both the IL-1 β and the IL1α [24].  In IL-1 mediated autoinflammatory diseases; 
i.e. cryopoyrin-associated periodic syndrome and SoJIA, anakinra has shown rapid efficacy 
on inflammatory symptoms at doses ranging from 2 to 10mg/kg, with a very good safety 
profile due to its very short serum half-life (6 hours) [20, 25].  Similarly, in our retrospective 
study, in all febrile patients, fever disappeared rapidly, within a few hours to a maximum of 
six days in one case. The effect on other symptoms of KD could not be evaluated 
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retrospectively due to missing information. Of interest, persistent inflammation with or 
without fever was another reason to use anakinra, which induced a decrease of 2 to 3 fold of 
the CRP levels within 48h. The efficacy on cardiac abnormalities was difficult to assess, 
because anakinra dosing and timing of cardiac measurements were not standardized. 
However, and contrary to what one might have thought by referring to the murine model, 
the effect of anakinra on patients' coronaries was neither fast nor striking [11]. Overall and 
after various regimens of anakinra treatment, coronary dilatations decreased or disappeared 
at last echography in all but one patient. Our results are consistent with three published 
patients with catastrophic KD, involving severe myocarditis and cardiac aneurysm in one and 
cardiac aneurysm and macrophage activation syndrome in another [15-17]. Both were finally 
successfully treated with anakinra at 8mg/kg and 2mg/kg respectively but required 
treatment duration of 2 and 5 months, respectively, to achieve complete cardiac recovery.  
Anakinra was given late in the course of KD, at an average of 25 days after the onset of 
symptoms and in association with other treatments in 7/11 patients. With small case 
numbers, it is not possible to separate the role of anakinra from the other agents used 
alongside, or from the natural history of waxing and waning inflammation and aneurysmal 
dilatation in KD. All but two patients had severe coronary dilatations. In the 
LCWE(Lactobacillus casei cell wall extract)-induced mouse vasculitis model, anakinra was 
able to prevent aortic aneurysms and to improve cardiac ejection fraction by controlling 
myocarditis, suggesting that early use of anakinra might better prevent or treat early 
coronary lesions [11].  Patient 11, with KD-related shock syndrome due to severe myocarditis 
had dramatic response on treatment by anakinra at 6mg/kg. One patient (4) with rapid 
increase of coronary aneurysms died of massive pericardial hemorrhage probably due to 
aneurysm rupture. This case is questioning and similar observation of rapidly increasing 
coronary aneurysms was recently reported in two on four patients with IVIG resistant KD 
treated with anti -IL-6 receptor (tocilizumab) [26]. As these are isolated observations and 
that the natural history of KD can produce the same effects, it is impossible to conclude in an 
inductive effect of these biotherapies on endothelial inflammation. Similar cases under 
glucocorticoid therapy have led to discontinuation of this treatment for years and in the 
obvious absence of controlled studies. 
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In conclusion, our retrospective study supports further investigation of the role for IL1 
blockade in the treatment of KD, especially in patients with persistent clinical and biological 
inflammation. Indeed, all but one patient (who died early) reported herein with difficult to 
treat KD, had rapid response to anakinra at various doses both on inflammatory symptoms 
and on biological inflammation, even two of them were already afebrile. Unfortunately, the 
heterogeneity of our data collected retrospectively does not allow concluding on efficacy of 
anakinra alone on coronary dilatations. More robust data will be available soon from the 
two Phase II ongoing trials, KAWAKINRA using anakinra treatment early after one failure of 
IVIG treatment (European Clinical Trials no. 2014-002715-41) and ANAKID (ClinicalTrials.gov 
identifier: NCT02179853), focused on patients with coronary giant aneurysms [27, 28].   
List of abbreviations and acronyms  
KD: Kawasaki disease 
IVIG: intravenous immunoglobulin 
SoJIA: Systemic onset juvenile idiopathic arthritis 
IL-1: Interleukin 1 
AHA: American Heart association 
CRP: C-reactive protein 
ESR: Erythrocyte sedimentation rate 
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Table 1.  The main clinical symptoms of 11 KD patients treated with anakinra. M= Male F= Female,  
Patients gender Age at 
disease 
onset 
(years) 
Diagnosis 
delay  
(days) 
Length 
of 
fever 
(days) 
Cervical 
adenitis 
> 1.5 
cm 
Bilateral non 
purulent 
conjunctivitis 
Modifications 
of oral 
mucosae 
Diffuse 
exanthema 
Modifications 
of extremities 
Irritability Other clinical 
signs 
Delay to first 
echocardiography  
(days) 
Coronary 
abnormalities at 
first 
echocardiography 
 
1 M 5 4 12 Yes Yes Yes Yes Yes Yes Hepatomegaly 4 Yes 
2 M 4.2 3 15 Yes Yes Yes Yes Yes Yes Hepatomegaly, 
Splenomegaly 
Neck pain 
3 Yes 
3 M 1.9 6 13 Yes Yes Yes Yes Yes Yes Hepatomegaly 12 No 
4 M 0.4 8 11 No Yes Yes Yes Yes Yes Seat erythema, 
Hepatomegaly,  
Splenomegaly 
Hypotonia 
8 Yes 
5 M 0.3 4 20 Yes Yes Yes Yes Yes Yes Hepatomegaly,  
Seat erythema, 
Arthritis 
4 Yes 
6 F 0.7 26 41 Yes Yes No Yes Yes Unknown Abdominal 
pain 
10 No 
7 M 2.8 4 10 Yes Yes Yes Yes No Yes diarrhea 8 Yes 
8 F 0.4 50 15 No Yes No Yes Yes Yes Perineal 
desquamation 
Kawasaki 
shock 
syndrome,   
Hepatomegaly 
High blood 
pressure 
37 No 
9 M 1.9 8 10 No Yes Yes Yes Yes Yes Neck pain 12 Yes 
10 M 9.0 9 11 Yes Yes Yes No Yes No Neck pain 9 Yes 
11 F 0.3 19 31 No Yes No Yes Yes Yes Diarrhea, 
Hepatomegaly, 
hypotonia 
Kawasaki 
shock 
syndrome,   
10 No 
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Figure 1:  Levels of CRP before and after Anakinra in the 11 patients . 
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Table 2.  Main initial biological results  and peak of leucocytes and platelets in  our 11 patients with Kawasaki disease. 
 
 
Patients Delay between initial 
blood test and disease 
onset  (days) 
Leucocytes 
/mm3 
Neutrophils 
/mm3 
Lymphocytes 
/mm3 
Platelets 
/ mm3 
Hemoglobin 
g/dl 
CRP 
mg/L 
Peak of leucocytes 
(days from disease 
onset) 
Peak of leucocytes 
/mm3 
Peak of platelets 
/mm3 
1 3 20 000 15 430 2460 306 000 13 190 3 20 000 . 
2 3 26 790 23 360 2060 313 000 11,2 162 10 51 410 2 287 000 
3 5 9 100 6 470 1380 289 000 10,4 280 12 14 000 1 320 000 
4 1 16 000 12 300 2300 402 000 11 82 12 73 120 941 000 
5 1 22 300 14 670 5750 160 000 9,3 98 6 30 070 1 600 000 
6 26 5 430 2 540 2100 423 000 9 35 36 17 720 453 000 
7 7 20 400 13 600 5200 446 000 11,4 129 7 20 400 736 000 
8 37 26 900 . . 349 000 9,1 110 46 43 000 1 175 000 
9 5 16 300 13 400 1800 447 000 9,6 273 17 24 400 934 000 
10 13 6 400 2 300 3200 114 000 11,5 38,8 13 6 400 506 000 
11 0 28 000 23 000 2500 388 000 9,5 116 . . 700 000 
Median  5 20 000 13 500 2380 349 000 10,4 116 12 22 400 937 500 
Mean  9,2 17 965 12 707 2875 330 636 10,5 138 16 30 052 1 065 200 
 
 
 
 
 
 
 
 
Table 3.  Anakinra and evolution on fever, CRP and cardiac complications for our 11 KD patients. 
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Patients Age at 
disease 
onset 
(years) 
Delay to 
1st 
treatment  
(days) 
Delay to 
Anakinra 
(days) 
 
Indication  Number 
of 
treatment 
performed 
before 
anakinra 
Initial 
dosage 
 
(mg/kg) 
Maximal 
dosage 
 
(mg/kg) 
CRP 
before 
anakinra 
(days 
before) 
CRP 
after 
anakinra 
(days 
after) 
Echocardiography 
before anakinra 
mm (z-score) 
 (days before)  
Echocardiography 
after anakinra 
(days after) 
Last echocardiography 
(days after anakinra) 
Length of 
treatment 
with anakinra 
(days) 
Efficacy 
on fever and 
inflammation 
Coronary 
changes 
after 
anakinra 
1 5 4 12 PF, PD 2 2 2 111  
(0) 
67 
(2) 
RCA 5 mm        (+10) 
LAD 5.5 mm      (+8)  
 (0) 
RCA 6.5 mm(+12.4) 
LAD 7.6 mm  (+15.6) 
(5) 
RCA 4 mm (+6) 
LAD 7 mm(+14) 
(139) 
81 Yes  Decrease 
2 4.2 3 15 PF, PI 4 2 2 40 
(0) 
17 
(2) 
RCA 2.5mm   (+0.9) 
LAD 2 mm       (+0.6) 
LMCA 3.5 mm(+2.7) 
(0) 
RCA 2.7 mm   (+1.4) 
LAD  1.8 mm   (-0.2) 
LMCA 3.2 mm (+2.0) 
(5) 
RCA 2.1mm( -0.2) 
LAD 2,1 mm( -0,2) 
LMCA 2 mm( -0,1) 
(185) 
25 Yes  Decrease 
3 1.9 6 13 PF, PI 3 2 2 94  
(0) 
23 
(2) 
RCA 2.5 mm(+2.5) 
LMCA 2.6 mm  (+1.2) 
 (-1) 
Normal coronary 
artery  
(10) 
Normal  
 
(108) 
13 Yes  Decrease 
4 0.4 9 15 PD, PI,  
 
2 4 6 48 
(0) 
42 
(2) 
RCA 5.8 mm    (+12.3) 
LAD 5.3 mm    (+12.4) 
LMCA 5.3 mm (+10.4) 
(-1) 
RCA 7.3 mm   (+16.8) 
LAD 6 mm      (+14.7) 
LMCA 5.5 mm(+11.1)  
(1) 
RCA 9mm      (+21.4) 
LMCA 9mm   (+21.7) 
Pericarditis 
(6) 
6 No Increase 
Death  
5 0.3 4 24 PF, PD 5 2 2 31 
(0) 
20 
(2) 
RCA 2.6 mm    (+3.8) 
LAD 2.6 mm    (+4.6) 
LMCA 3.2 mm (+5.0) 
(0) 
RCA 3.8 mm     (+7.3) 
LAD 4 mm        (+9.2) 
LMCA 2.4 mm (+2.6) 
(12) 
RCA 3.0 mm     (+5.0) 
LAD 3.2 mm     (+6.5) 
LMCA 2.4 mm  (+2.6) 
 (20) 
ongoing Yes Decrease 
6 0.7 26 35 PD, PI 3 4 4 25 
(-1) 
2 
(0) 
RCA 3.5 mm    (+5.9) 
LAD 3 mm       (+5.4) 
LMCA 3.6 mm (+5.6) 
(-2) 
RCA 3.5 mm    (+5.9) 
LAD 3 mm       (+5.4) 
LMCA 3.6 mm (+5.6) 
(2) 
RCA: normal 
LAD 2.9            (+2.9) 
LMCA 4.0         (+3.1) 
(24) 
ongoing Yes  Decrease 
7 2.8 4 8 PF, PI, 
PC 
3 6 6 92 
(0) 
34 
(1) 
RCA  3.2 mm    (+3.8) 
LAD 4.5 mm     (+5.2) 
LMCA  4.5 mm  (+5.8) 
(0) 
. RCA 2.4 mm    (+1.4) 
LAD 1.5 mm    (-1.5) 
LMCA 2.5 mm (+0.9) 
(161) 
41 Yes  Decrease 
8 0.4 50 87 PF, PD 5 4 4 . 27 
(12) 
RCA 6 mm       (+12.3) 
LAD 4.6 mm  
LMCA 3mm 
 
(-12) 
RCA 5.7 mm 
LAD 3.2 mm 
LMCA 3.2mm 
 
(1) 
RCA 4.8 mm 
LMCA 3.9mm 
(28) 
Normal coronary arteries at 
cardiac catheter   
(245) 
50 Yes Decrease 
9 1.9 8 14 PF, PD, 4 7.5 7.5 50 
(-1) 
17 
(1) 
RCA 4mm         (+6.6) 
LAD 4.2 mm      (+7.7) 
LMCA 2.2 mm   (+0.4) 
(-2) 
RCA 5.4 mm (+10.3) 
LAD 5 mm    (+10) 
LMCA 3 mm (+2.0) 
(6) 
RCA   2.7 mm   (+0.6) 
LAD  2.4 mm     (+1.6) 
LMCA 2.5 mm  (+0.0) 
(420) 
42 Yes  Decrease 
10 9.0 9 13 PD 2 4 4 39 
(0) 
24 
(1) 
RCA 6.6 mm    (+10.9) 
LAD 5mm         (+9.1) 
LMCA 6mm      (+7.2) 
(-1) 
RCA 6.7 mm 
LAD 5.8mm 
LMCA 6.6 mm 
(2) 
RCA 6.7 mm      (+11) 
LAD 2.2mm       (-0.3) 
LMCA 6.7 mm   (+8.5) 
(78) 
43 No Stable 
/Decrease 
11 0.3 19 35 PF, KCS, 
PI, PC 
3 6 8 320 
(-4) 
5 
(10) 
RCA 3.2 mm 
LMCA 4.2 mm 
LAD 3.4 mm 
(-12) 
RCA 3.2 mm 
LMCA 4.2 mm 
LAD 3.4 mm 
(7) 
RCA 2.8 mm 
LMCA 2.5 mm 
LAD 2.5 mm 
(95) 
73 Yes   Decrease 
 17 
PF: persistant fever; KCS : Kawasaki shock syndrome, PD: progressive coronary dilatation, PI: Persistant blood inflammation, PC: persistant 
clinical symptoms 
 
 
 
 
